Article Details

Esperion Therapeutics (NASDAQ:ESPR) Downgraded by The Goldman Sachs Group to "Sell"

Retrieved on: 2021-02-09 12:22:30

Tags for this article:

Click the tags to see associated articles and topics

Esperion Therapeutics (NASDAQ:ESPR) Downgraded by The Goldman Sachs Group to "Sell". View article details on hiswai:

Excerpt

The Goldman Sachs Group's price target points to a potential downside of 34.94% from the company's current price. A number of other equities analysts ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo